Ateneo
Dipartimenti
Didattica
Orientamento
Studenti
Laureati
Personale
International
Partner e Aziende
Nuovissimo Abbecedario

Documento senza titolo

FANELLI MIRCO
Tel. 0722-304951 Fax. 0721-862832 Email mirco.fanelli@uniurb.it

Curriculum Vitae



  • 1996 / 1999 – Ricercatore borsista (AIRC) presso la Divisione di Oncologia Sperimentale D, dell’Istituto Nazionale dei Tumori di Milano, diretta dal Prof. G. Parmiani. Attività di ricerca svolta in collaborazione con il Dip. di Oncologia Sperimentale, dell’Istituto Europeo di Oncologia di Milano, diretto dal Prof. Pier Giuseppe Pelicci.


  • 1999 / 2000 – Ricercatore borsista (AIRC-IEO) presso il Dipartimento di Oncologia Sperimentale dell’Istituto Europeo di Oncologia di Milano, diretto dal Prof. Pier Giuseppe Pelicci.


  • 1999 – Vincitore di una Borsa di Studio della Fondazione Italiana per la Ricerca sul Cancro (FIRC) finalizzata a studi specialistici all’estero. Attività di ricerca svolta presso il laboratorio del Prof. Bryan M. Turner – School of Medicine, University of Birmingham – England.


  • 2001 / 2002 – Attività di ricerca svolta come Operatore Tecnico presso il Laboratorio di Biochimica Applicata – Dipartimento di Scienze Morfologiche e Biochimiche Comparate – dell’Università degli Studi di Camerino. Cultore del settore disciplinare BIO/10, Chimica Biologica – Facoltà di Scienze Matematiche, Fisiche e Naturali - Università degli Studi di Camerino.


  • Marzo 2002 ad oggi – Ricercatore (settore disciplinare MED/04 – Patologia Generale) presso la Facoltà di Scienze MM.FF.NN. dell’Università degli Studi di Urbino – Coordinatore del Laboratorio di Patologia Molecolare "M. Paola", presso il Centro di Biotecnologie di Fano.

Attività di Ricerca

Molecular Oncology - Cancer Epigenetic - Drug discovery

Pubblicazioni

1.      AMBROGINI P, LATTANZI D, CIUFFOLI S, BETTI M, FANELLI M, CUPPINI R (2013). 
Physical exercise and environment exploration affect synaptogenesis in adult-generated neurons in the rat dentate gyrus: possible role of BDNF. 
BRAIN RESEARCH (accepted)
 
2.     AMATORI S, AMBROSI G, FANELLI M, FORMICA M, FUSI V, GIORGI L, MACEDI E, MICHELONI M, PAOLI P, PONTELLINI R, ROSSI P, VARRESE MA (2012). 
Multi-use NBD-based tetra-amino macrocycle: fluorescent probe for metals and anions and live cell marker. 
CHEMISTRY 18(14):4274-4284
 
3.     TERENZI A, FANELLI M, AMBROSI G, AMATORI S, FUSI V, GIORGI L, TURCO LIVERI V, BARONE G (2012). 
DNA binding and antiproliferative activity toward human carcinoma cells of copper (ii) and zinc (ii) complexes of a 2,5-diphenyl [1,3,4]oxadiazole derivative. 
DALTON TRANS. 41(15):4389-4395
 
4.     AMATORI S, AMBROSI G, FANELLI M, FORMICA M, FUSI V, GIORGI L, MACEDI E, MICHELONI M, PAOLI P, PONTELLINI R, ROSSI P (2012). 
Synthesis, basicity, structural characterization and biochemical properties of two [(3-Hydroxy-4-pyron-2-yl)methyl]amine derivatives showing anti-neoplastic features. 
J ORG CHEM 77(5):2207-2218
 
5.     FANELLI M, AMATORI S, BAROZZI I, MINUCCI S (2011). 
Chromatin immunoprecipitation and high-throughput sequencing from paraffin-embedded pathology tissue. 
NATURE PROTOCOLS 6(12):1905-1919
 
6.     DE SANTI M, GALLUZZI L, LUCARINI S, PAOLETTI MF, FRATERNALE A, DURANTI A, DE MARCO C, FANELLI M., ZAFFARONI N, BRANDI G, MAGNANI M (2011). 
The indole-3-carbinol cyclic tetrameric derivative CTet inhibits cell proliferation via overexpression of p21/CDKN1A in both estrogen receptor positive and triple negative breast cancer cell lines. 
BREAST CANCER RESEARCH, 13:R33
 
7.     AMATORI S, BAGALONI I, VITI D, FANELLI M. (2011). 
Premature senescence induced by DNA demethylating agent (Decitabine) as therapeutic option for malignant pleural mesothelioma. 
LUNG CANCER, vol. 71:113-117
 
8.     RIPPO MR, VILLANOVA F, TOMASSONI ARDORI F, GRACIOTTI L, AMATORI S, MANZOTTI S, FANELLI M., GIGANTE A, PROCOPIO A (2010). 
Dexamethasone affects Fas- and serum deprivation- induced cell death of human osteoblastic cells through survivin regulation. 
INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY 23(4):1153-1165
 
9.     FANELLI M., AMATORI S, BAROZZI I, SONCINI M, DAL ZUFFO R, BUCCI G, CAPRA M, QUARTO M, DELLINO GI, MERCURIO C, ALCALAY M, VIALE G, PELICCI PG, MINUCCI S (2010). 
Pathology tissue–chromatin immunoprecipitation, coupled with high-throughput sequencing, allows the epigenetic profiling of patient samples. 
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE USA 107(50):21535-21540
 
10.  AMATORI S, BAGALONI I, DONATI B, FANELLI M. (2010). 
Malten, a new synthetic molecule showing in vitro antiproliferative activity against tumor cells and induction of complex DNA structural alterations. 
BRITISH JOURNAL OF CANCER, 103(2): 239-248
 
11.  AMATORI S, BAGALONI I, DONATI B, FANELLI M. (2010). DNA demethylating antineoplastic strategies: a comparative point of view. 
GENES & CANCER  1(3):197-209
 
12.  AMBROGINI P, CUPPINI R, LATTANZI D, CIUFFOLI S, FRONTINI A, FANELLI M. (2009). 
Synaptogenesis in adult-generated hippocampal granule cells is affected by behavioral experiences. HIPPOCAMPUS 20(7):799-810
 
13.  AMATORI S, PAPALINI F, LAZZARINI R, DONATI B, BAGALONI I, RIPPO MR, PROCOPIO A, PELICCI PG, CATALANO A, FANELLI M. (2009). Decitabine, differently from DNMT1 silencing, exerts its antiproliferative activity through p21 upregulation in Malignant Pleural Mesothelioma (MPM) cells. LUNG CANCER 66(2):184-190
 
14.  FANELLI M., CAPRODOSSI S, RICCI-VITIANI L, PORCELLINI A, TOMASSONI-ARDORI F, ANDREONI F, MAGNANI M, DE MARIA R, SANTONI A, MINUCCI S, PELICCI PG (2008). Loss of pericentromeric DNA methylation pattern in human  Glioblastoma is associated with altered DNA methyltransferases  (DNMTs) expression and involves the Stem Cell compartment. ONCOGENE, vol. 27(3):358-365
 
15. AMBROGINI P, MINELLI A, LATTANZI D, CIUFFOLI S, FANELLI M., CUPPINI R (2006). Synaptically-silent immature neurons show GABA and glutamate receptor-mediated currents in adult rat dentate gyrus. ARCHIVES ITALIENNES DE BIOLOGIE 144(2):115-126
 
16.  CAPRODOSSI S, GALLUZZI L, BIAGETTI S, DELLA CHIARA G, PELICCI P.G, MAGNANI M, FANELLI M. (2005). In vitro inhibition of Promyelocytic Leukemia/Retinoic Acid Receptor alpha (PML/RARalpha) expression and leukemogenic activity by DNA/LNA chimeric antisense oligos. ONCOLOGY RESEARCH, 16(3):157-166
 
17.  CAPRODOSSI S, PEDINOTTI M, AMANTINI C, SANTONI G, MINUCCI S, PELICCI PG, FANELLI M. (2005). Differentiation response of Acute Promyelocytic Leukemia (APL) cells and PML/RARalpha leukemogenic activity studies by Real-Time RT-PCR. MOLECULAR BIOTECHNOLOGY 30(3):231-238
 
18.  FANELLI M., FANTOZZI A, DE LUCA P, CAPRODOSSI S, MATSUZAWA S-I, LAZAR MA, PELICCI PG, MINUCCI S (2004). The coiled-coil domain is the structural determinant for SIAH-mediated degradation of PML and other TRIM proteins by the proteasome. THE JOURNAL OF BIOLOGICAL CHEMISTRY 279(7):5374-5379
 
19.  DI CROCE L, RAKER VA, CORSARO M, FAZI F, FANELLI M., FARETTA M, FUKS F, LO COCO F, KOUZARIDES T, NERVI C, MINUCCI S, PELICCI PG (2002). Methyltransferase recruitment and DNA Hypermethylation of target promoters by an oncogenic transcription factor. SCIENCE, vol. 295(5557):1079-1082
 
20.  M-J. MOZZICONACCI, A. ROSENAUER, A. RESTOUIN, FANELLI M., W. SHAO, F. FERNANDEZ, Y. TOIRON, J. VISCARDI, C. GAMBACORTI-PASSERINI, W.H. MILLER JR., M. LAFAGE-POCHITALOFF (2002). Molecular cytogenetics of the acute promyelocytic leukemia-derived cell line NB4 and of four all-trans retinoic acid-resistant subclones. GENES, CHROMOSOMES & CANCER, vol. 35; p. 261-270
 
21.  PUPPO F., GRISERI P., FANELLI M., SCHENA F., ROMEO G., PELICCI P.G., CECCHERINI I., RAVAZZOLO R., PATRONE G. (2002). Cell-line specific chromatin acetylation at the Sox10-Pax3 enhancer site modulates the RET proto-oncogene expression. FEBS LETTERS 523(1-3):123-127
 
22.  FANELLI M., PIER PIUSEPPE PELICCI (1999). Relationship between degradation of PML-RAR alpha and differentiation. BLOOD 94(4):1478-1479
 
23.  FANELLI M., S. MINUCCI, V. GELMETTI, C. NERVI, C. GAMBACORTI-PASSERINI, P.G. PELICCI (1999). Constitutive degradation of PML/RARalpha through the proteasome pathway mediates retinoic acid resistance. BLOOD 93(5):1477-1481
 
24.  FR. GRIGNANI, V. GELMETTI, FANELLI M., D. ROGAIA, S. DE MATTEIS, F. FERRARA, F. GRIGNANI, C. NERVI, P.G. PELICCI (1999). Formation of PML/RARa high molecular weight nuclear complexes through the PML coiled-coil region is essential for the PML/RARa-mediated retinoic acid response. ONCOGENE 18(46):6313-6321
 
25.  C. NERVI, F.F. FERRARA, FANELLI M., M. RIPPO, B. TOMASSINI, P.F. FERRUCCI, M. RUTHARDT, V. GELMETTI, D. DIVERIO, FR. GRIGNANI, P.G. PELICCI, R. TESTI (1998). Caspases mediate retinoic acid induced degradation of the acute promyelocytic leukemia PML/RARalpha fusion protein. BLOOD 92(7):2244-2251
 
26.  F. GRIGNANI, S. DE MATTEIS, C. NERVI, L. TOMASSONI, V. GELMETTI, M. CIOCE, FANELLI M., M. RUTHARDT, F.F. FERRARA, I. ZAMIR, C. SEISER, F. GRIGNANI, M.A. LAZAR, S. MINUCCI, P.G. PELICCI (1998). Fusion proteins of the retinoic acid-a recruit histone deacetylase in promyelocytic leukaemia. NATURE 391(6669):815-818,
 
27.  V. GELMETTI, J. ZHANG, FANELLI M., S. MINUCCI, P.G. PELICCI, MITCHELL A. LAZAR (1998). Aberrant recruitment of the Nuclear Receptor Corepressor-Histone Deacetylase complex by the acute myeloid leukemia fusion partner ETO. MOLECULAR AND CELLULAR BIOLOGY 18(12):7185-7191
 
28.  W.SHAO, FANELLI M., F. FERRARA, R. PICCIONI, A. ROSENAUER, K. DAVISON, W.W. LAMPH, S. WAXMAN, P.G. PELICCI, F. LO COCO, U. TESTA, C. PESCHLE, C. GAMBACORTI-PASSERINI, C. NERVI, W.H. MILLER JR. (1998). Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cells. JOURNAL OF THE NATIONAL CANCER INSTITUTE 90(2):124-133
 
29.  C. GAMBACORTI-PASSERINI, P. LE COUTRE, L. MOLOGNI, FANELLI M., C. BERTAZZOLI, E. MARCHESI, A. BIONDI, G.M. CORNEO, D. BELOTTI, E. POGLIANI, N.B. LYDON (1997). Inhibition of the ABL Kinase activity blocks the proliferation of BCR/ABL leukemic cells and induces apoptosis. BLOOD CELLS, MOLECULES, & DISEASES, vol. 23; p. 380-394
 
30.  M. EMANUELLI, N. RAFFAELLI, A. AMICI, FANELLI M., S. RUGGIERI, G. MAGNI (1996). Three-minute high-performance liquid chromatographic assay for NMN adenylyltransferase using a 20-mm-long reversed-phase column. JOURNAL OF CHROMATOGRAPHY B. BIOMEDICAL APPLICATIONS, vol. 676; p. 13-18
 
 
BREVETTI
1.     FANELLI M., FUSI V. (2009). DERIVATIVES OF [(3-HYDROXY-4-PYRON-2-YL)METHYL]-AMINE AND USE THEREOF AS ANTI-NEOPLASTIC DRUGS. PCT/IB2009/007579, Fanelli-Fusi.
 

2.     FANELLI M., FUSI V. (2008). DERIVATI DI [(3-IDROSSI-4-PIRON-2-IL)METIL]-AMINA E LORO USO COME FARMACI ANTI-NEOPLASTICI. TO2008A000888, Fanelli-Fusi.